Skip to main content
Supplement Research and Comparison WebsiteBest Price GuaranteeAbout Us
Supplement Research and Comparison Website

Abstract

The effects of administration of bifidobacteria on the intestinal microbiota in low-birth-weight infants, and the transition of each strain of administered bifidobacteria were investigated. A single strain of Bifidobacterium breve M-16V (5 × 10(8); one-species group) or a mixture of three species composed of B. breve M-16V, Bifidobacterium longum subsp. infantis M-63 and B. longum subsp. longum BB536 (5 × 10(8) of each strain; three-species group) were administered daily for 6 weeks. Bifidobacterial administration significantly increased the detection rates and cell numbers of bifidobacteria in the feces (weeks 1-6). The proportion of bifidobacteria was significantly higher in the one-species group at weeks 1-4, and in the three-species group at weeks 1-6 compared with the control group. Furthermore, the proportion of bifidobacteria in the three-species group was significantly higher than that in the one-species group at weeks 1 and 6. The proportion of infants with bifidobacteria-predominant microbiota was significantly higher in the three-species group than in the control group during the test period. The detection rates of Clostridium were lower in the bifidobacteria-administered groups. The proportions of Enterobacteriaceae were significantly lower in the three-species group compared to the other groups (weeks 4 and 6). Among the three strains administered, B. breve M-16V and Bifidobacterium infantis M-63 were detected in 85% or more of the infants during the administration period, while B. longum BB536 was detected in 40% or less. Compared with administration of one species, administration of three species of bifidobacteria resulted in earlier formation of a bifidobacteria-predominant fecal microbiota and maintenance of this microbiota.

Keywords: Bifidobacteria; Intestinal microbiota; Premature infant.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Bifidobacterium breve M-16VIncreased Bifidobacterial LevelsBeneficial
Large
Bifidobacterium breve M-16VReduced Detection Rates of ClostridiumBeneficial
Moderate
Bifidobacterium infantisFormation of Bifidobacteria Predominant MicrobiotaBeneficial
Large
Bifidobacterium infantisReduced Detection Rates of ClostridiumBeneficial
Moderate
Bifidobacterium infantisReduced Enterobacteriaceae CountsBeneficial
Large
Bifidobacterium infantis M-63Increased Proportion of Bifidobacteria in Gut MicrobiotaBeneficial
Large
Bifidobacterium infantis M-63Reduced Detection Rates of ClostridiumBeneficial
Moderate
Bifidobacterium infantis M-63Reduced Enterobacteriaceae CountsBeneficial
Large
Bifidobacterium longum subsp. infantisIncreased Proportion of Bifidobacteria in Gut MicrobiotaBeneficial
Large
Bifidobacterium longum subsp. infantisReduced Enterobacteriaceae CountsBeneficial
Large
Bifidobacterium longum subsp. infantis M-63Formation of Bifidobacteria Predominant MicrobiotaBeneficial
Large
Bifidobacterium longum subsp. infantis M-63Increased Detection of BifidobacteriaBeneficial
Large
Bifidobacterium longum subsp. infantis M-63Increased Proportion of Bifidobacteria in Gut MicrobiotaBeneficial
Large
Bifidobacterium longum subsp. infantis M-63Reduced Enterobacteriaceae CountsBeneficial
Large
⬆ Back to top
Unsubscribe anytime. See our Privacy Policy.
Pillser
Supplement Research and Comparison Website: evidence-based information about supplements, their benefits, potential risks, and their efficacy.

Join Our Community

Statements on this website have not been reviewed by the U.S. Food and Drug Administration. These products are not meant to diagnose, treat, cure, or prevent any disease. The information here is not a replacement for personal medical advice.